H.C. Wainwright lowered the firm’s price target on Botanix Pharmaceuticals (BXPHF) to A$1 from A$2 and keeps a Buy rating on the shares. The firm cites the ongoing equity raise announced in February for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BXPHF:
- Botanix Pharmaceuticals’ Sofdra Drives Growth Amid Cash Strain
- Botanix outlines limits and risks in 2026 half-year investor briefing
- Botanix flags solvency risk as April vote decides fate of capital raising
- Botanix Wins ASX Waiver to Enable Shareholder Vote on Capital Raising
- Botanix corrects prior-period revenue typo as half-year sales surge but losses widen